Cyrus Mugo1,2, Alvin Onyango3, Irene N Njuguna4, Caren W Mburu4, Barbra A Richardson4,5, Laura Oyiengo6, Irene Inwani7, Grace John-Stewart2,4,8,9, Dalton C Wamalwa3, Pamela K Kohler4,10. 1. Department of Research and Programs, Kenyatta National Hospital, Nairobi, Kenya. 2. Departments of Epidemiology; and. 3. Department of Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya. 4. Global Health, University of Washington, Seattle, WA. 5. Department of Biostatistics, University of Washington, Seattle, WA. 6. National AIDS and STI Control Programme, Ministry of Health, Nairobi, Kenya. 7. Department of Pediatrics, Kenyatta National Hospital, Nairobi, Kenya; and. 8. Departments of Medicine. 9. Pediatrics; and. 10. Child, Family, and Population Health Nursing, University of Washington, Seattle, WA.
Abstract
BACKGROUND: Repeat HIV viral load (VL) testing is required after unsuppressed VL to confirm treatment failure. We assessed proportion of adolescents and young adults living with HIV (AYALHIV) in Kenya with a confirmatory VL test and time to repeat testing. DESIGN: A retrospective analysis of longitudinal data abstracted from Kenya's national VL database. METHODS: VL data for AYALHIV who were 10-24 year old between April 2017 and May 2019 were abstracted from 117 HIV care clinics. Records were eligible if at least one VL test was performed ≥6 months after antiretroviral therapy (ART) initiation. The proportion of unsuppressed AYALHIV (≥1000 copies/mL) and time in months between first unsuppressed VL and repeat VL was determined. RESULTS: We abstracted 40,928 VL records for 23,969 AYALHIV; of whom, 17,092 (71%) were eligible for this analysis. Of these, 12,122 (71%) were women, median age of 19 years [interquartile range (IQR): 13-23], and median ART duration of 38 months (IQR: 16-76). Among eligible AYALHIV, 4010 (23%) had an unsuppressed VL at first eligible measurement. Only 316 (8%) of the unsuppressed AYALHIV had a repeat VL within 3 months and 1176 (29%) within 6 months. Among 2311 virally unsuppressed AYALHIV with a repeat VL, the median time between the first and the repeat VL was 6 months (IQR: 4-8), with 1330 (58%) having confirmed treatment failure. CONCLUSIONS: One-quarter of AYALHIV on ART had unsuppressed VL, with less than a third receiving a repeat VL within 6 months. Strategies to improve VL testing practices are needed to improve AYALHIV's outcomes.
BACKGROUND: Repeat HIV viral load (VL) testing is required after unsuppressed VL to confirm treatment failure. We assessed proportion of adolescents and young adults living with HIV (AYALHIV) in Kenya with a confirmatory VL test and time to repeat testing. DESIGN: A retrospective analysis of longitudinal data abstracted from Kenya's national VL database. METHODS: VL data for AYALHIV who were 10-24 year old between April 2017 and May 2019 were abstracted from 117 HIV care clinics. Records were eligible if at least one VL test was performed ≥6 months after antiretroviral therapy (ART) initiation. The proportion of unsuppressed AYALHIV (≥1000 copies/mL) and time in months between first unsuppressed VL and repeat VL was determined. RESULTS: We abstracted 40,928 VL records for 23,969 AYALHIV; of whom, 17,092 (71%) were eligible for this analysis. Of these, 12,122 (71%) were women, median age of 19 years [interquartile range (IQR): 13-23], and median ART duration of 38 months (IQR: 16-76). Among eligible AYALHIV, 4010 (23%) had an unsuppressed VL at first eligible measurement. Only 316 (8%) of the unsuppressed AYALHIV had a repeat VL within 3 months and 1176 (29%) within 6 months. Among 2311 virally unsuppressed AYALHIV with a repeat VL, the median time between the first and the repeat VL was 6 months (IQR: 4-8), with 1330 (58%) having confirmed treatment failure. CONCLUSIONS: One-quarter of AYALHIV on ART had unsuppressed VL, with less than a third receiving a repeat VL within 6 months. Strategies to improve VL testing practices are needed to improve AYALHIV's outcomes.
Authors: M Mburu; M A Guzé; P Ong'wen; N Okoko; M Moghadassi; C R Cohen; E A Bukusi; H T Wolf Journal: Public Health Date: 2019-07-13 Impact factor: 2.427
Authors: Aimalohi A Ahonkhai; Bolanle Banigbe; Juliet Adeola; Abdulkabir B Adegoke; Susan Regan; Ingrid V Bassett; Ifeoma Idigbe; Elena Losina; Prosper Okonkwo; Kenneth A Freedberg Journal: J Adolesc Health Date: 2016-06-18 Impact factor: 5.012
Authors: Kate S Wilson; Cyrus Mugo; David Bukusi; Irene Inwani; Anjuli D Wagner; Helen Moraa; Tamara Owens; Joseph B Babigumira; Barbra A Richardson; Grace C John-Stewart; Jennifer A Slyker; Dalton C Wamalwa; Pamela K Kohler Journal: Trials Date: 2017-12-28 Impact factor: 2.279
Authors: Kristin Brown; Daniel B Williams; Steve Kinchen; Suzue Saito; Elizabeth Radin; Hetal Patel; Andrea Low; Stephen Delgado; Owen Mugurungi; Godfrey Musuka; Beth A Tippett Barr; E Amaka Nwankwo-Igomu; Leala Ruangtragool; Avi J Hakim; Thokozani Kalua; Rose Nyirenda; Gertrude Chipungu; Andrew Auld; Evelyn Kim; Danielle Payne; Nellie Wadonda-Kabondo; Christine West; Elizabeth Brennan; Beth Deutsch; Anteneh Worku; Sasi Jonnalagadda; Lloyd B Mulenga; Kumbutso Dzekedzeke; Danielle T Barradas; Haotian Cai; Sundeep Gupta; Stanley Kamocha; Margaret A Riggs; Karampreet Sachathep; Wilford Kirungi; Joshua Musinguzi; Alex Opio; Sam Biraro; Elizabeth Bancroft; Jennifer Galbraith; Herbert Kiyingi; Mansoor Farahani; Wolfgang Hladik; Edith Nyangoma; Choice Ginindza; Zandile Masangane; Fortune Mhlanga; Zandile Mnisi; Pasipamire Munyaradzi; Amos Zwane; Sean Burke; Felix B Kayigamba; Harriet Nuwagaba-Biribonwoha; Ruben Sahabo; Trong T Ao; Chiara Draghi; Caroline Ryan; Neena M Philip; Fausta Mosha; Aroldia Mulokozi; Phausta Ntigiti; Angela A Ramadhani; Geoffrey R Somi; Cecilia Makafu; Veronicah Mugisha; Julius Zelothe; Kayla Lavilla; David W Lowrance; Rennatus Mdodo; Elizabeth Gummerson; Paul Stupp; Kyaw Thin; Koen Frederix; Stefania Davia; Amee M Schwitters; Stephen D McCracken; Yen T Duong; David Hoos; Bharat Parekh; Jessica E Justman; Andrew C Voetsch Journal: MMWR Morb Mortal Wkly Rep Date: 2018-01-12 Impact factor: 17.586
Authors: Amy L Slogrove; Michael Schomaker; Mary-Ann Davies; Paige Williams; Suna Balkan; Jihane Ben-Farhat; Nancy Calles; Kulkanya Chokephaibulkit; Charlotte Duff; Tanoh François Eboua; Adeodata Kekitiinwa-Rukyalekere; Nicola Maxwell; Jorge Pinto; George Seage; Chloe A Teasdale; Sebastian Wanless; Josiane Warszawski; Kara Wools-Kaloustian; Marcel Yotebieng; Venessa Timmerman; Intira J Collins; Ruth Goodall; Colette Smith; Kunjal Patel; Mary Paul; Diana Gibb; Rachel Vreeman; Elaine J Abrams; Rohan Hazra; Russell Van Dyke; Linda-Gail Bekker; Lynne Mofenson; Marissa Vicari; Shaffiq Essajee; Martina Penazzato; Gabriel Anabwani; Edith Q Mohapi; Peter N Kazembe; Makhosazana Hlatshwayo; Mwita Lumumba; Tessa Goetghebuer; Claire Thorne; Luisa Galli; Annemarie van Rossum; Carlo Giaquinto; Magdalena Marczynska; Laura Marques; Filipa Prata; Luminita Ene; Liubov Okhonskaia; Pablo Rojo; Claudia Fortuny; Lars Naver; Christoph Rudin; Sophie Le Coeur; Alla Volokha; Vanessa Rouzier; Regina Succi; Annette Sohn; Azar Kariminia; Andrew Edmonds; Patricia Lelo; Samuel Ayaya; Patricia Ongwen; Laura F Jefferys; Sam Phiri; Mwangelwa Mubiana-Mbewe; Shobna Sawry; Lorna Renner; Mariam Sylla; Mark J Abzug; Myron Levin; James Oleske; Miriam Chernoff; Shirley Traite; Murli Purswani; Ellen G Chadwick; Ali Judd; Valériane Leroy Journal: PLoS Med Date: 2018-03-01 Impact factor: 11.069
Authors: Kathleen Kehoe; Andrew Boulle; Priscilla R Tsondai; Jonathan Euvrard; Mary Ann Davies; Morna Cornell Journal: J Int AIDS Soc Date: 2020-05 Impact factor: 5.396
Authors: Esther Nasuuna; Joanita Kigozi; Lillian Babirye; Alex Muganzi; Nelson K Sewankambo; Damalie Nakanjako Journal: BMC Public Health Date: 2018-08-22 Impact factor: 3.295
Authors: Gillian Dougherty; Steve Akoth; Mark Hawken; Isaac Leting; Redempta Mutei; Catherine Ngugi; Doris Naitore; Fatima Tsiouris; Anne Wakoli; Lauren Walker; Miriam Rabkin Journal: BMJ Open Qual Date: 2022-08